<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this report is to document the use of bevacizumab as treatment of peripapillary subretinal neovascular membrane associated to idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This case reports a 31-year-old <z:mp ids='MP_0001261'>obese</z:mp> female with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001085'>papilledema</z:hpo> due to idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> that developed an <z:hpo ids='HP_0011009'>acute</z:hpo> submacular <z:mp ids='MP_0001914'>hemorrhage</z:mp> due to a <z:e sem="disease" ids="C1282209" disease_type="Disease or Syndrome" abbrv="">choroidal neovascular membrane</z:e> in her left eye </plain></SENT>
<SENT sid="2" pm="."><plain>Two separate intravitreal injections of bevacizumab (1.25 mg/0.5 ml) were administered with six weeks apart </plain></SENT>
<SENT sid="3" pm="."><plain>Fourteen weeks after the initial injection her visual acuity improved to 20/40 in her left eye with associated angiographic resolution of the <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Bevacizumab appears to be an effective option for patients who have subretinal neovascular membranes due to <z:hpo ids='HP_0001085'>papilledema</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Although <z:mp ids='MP_0005546'>choroidal neovascularization</z:mp> may have different pathogenic mechanisms, our case report demonstrates encouraging results without adverse ocular or systemic side effects </plain></SENT>
</text></document>